Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy

Gianni Testino, Alessandro Sumberaz, Filippo Ansaldi, Paolo Borro, Silvia Leone, A. Ornella Ancarani, Raffaella Gentile, Giancarlo Icardi

Research output: Contribution to journalArticle

Abstract

Background/Aims: This study aims at evaluating the efficacy of treatment with pegylated interferon (PEG-IFN) alfa-2b and ribavirin in patients with recurrent hepatitis C (genotype 1) after orthotopic liver transplantation (OLT) and the impact of this therapy on hepatic fibrosis at the end of conventional therapy and at the end of a period of maintenance treatment in non-responder patients. Methodology: Thirty-two consecutive patients diagnosed with recurrent HCV were considered candidates for antiviral therapy. Results: Ten patients (31.2%) interrupted therapy due to side effects; sustained virological response (SVR) was observed in 27.2%, sustained biochemical response (SBR) in 31.8% and NR in 40.9% of cases. Eighteen patients underwent a biopsy at the end of conventional treatment: improved fibrosis score in all patients with SVR, improved score in 1 patient with SBR and stable score in 6 patients with SBR, worse score in 1 NR patient and stable in 6 NR patients. Six NR patients with stable score submitted to a maintenance therapy: improved score in 1 patient and stable score in 5 patients. Conclusions: In recurrent hepatitis C, in spite of the type of response, treatment slows down hepatic fibrotic evolution.

Original languageEnglish
Pages (from-to)536-538
Number of pages3
JournalHepato-Gastroenterology
Volume58
Issue number106
Publication statusPublished - Mar 2011

Keywords

  • Fibrosis
  • Maintenance therapy
  • Orthotopic liver transplantation
  • Pegylated interferon
  • Recurrent hepatitis C
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy'. Together they form a unique fingerprint.

  • Cite this

    Testino, G., Sumberaz, A., Ansaldi, F., Borro, P., Leone, S., Ancarani, A. O., Gentile, R., & Icardi, G. (2011). Treatment of recurrent hepatitis C (genotype 1) with pegylated interferon alfa-2b and ribavirin combination and maintenance therapy. Hepato-Gastroenterology, 58(106), 536-538.